ERBB2 and cancer: Liquid biopsy analysis of HER-2/neu in cancer patients’ samples may be a possible alternative to solid tumour analysis: HER-2/neu released into the bloodstream by tumour cells has a huge biomarker potential to account for tumour heterogeneity compared to tissue biopsies.